Sanofi
Sanofi to invest €400 million on Singapore vaccine production site
April 12, 2021Sales and Marketing Sanofi, Vaccine
Sanofi have today announced a €400 million investment to create a unique vaccine production centre in Singapore, in partnership with …
New Sanofi Sarclisa treatment for multiple myeloma approved by FDA
April 1, 2021FDA, FDA Approval, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa drug has been approved by the FDA in combination with carfilzomib and dexamethasone (Kd) for the treatment of …
Phase III trial of Libtayo stopped early after positive overall survival results
March 15, 2021Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …
Sanofi and SIRION collaborate on AAV vector development to treat serious diseases
February 24, 2021Research and Development AAV vectors, SIRION, Sanofi
SIRION Biotech and Sanofi have entered into an agreement to develop effective medicines for illnesses impacting major human organs.
FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer
February 23, 2021Manufacturing and Production Cancer, Sanofi
The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …
GSK and Sanofi to begin new Phase II trial of their COVID-19 vaccine
February 22, 2021Sales and Marketing COVID, COVID Vaccine, COVID-19, GSK, Sanofi
GlaxoSmithKline (GSK) and Sanofi are set to begin a new Phase II study of their COVID-19 vaccine candidate, following setbacks …
FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma
February 10, 2021Research and Development Cancer, FDA, Sanofi
The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …
MHRA grants Promising Innovative Medicine Designation to Sanofi’s RSV drug
January 19, 2021Manufacturing and Production MHRA, Sanofi
The MHRA has granted a Promising Innovative Medicine (PIM) Designation to Sanofi’s nirsevimab, which is being investigated a passive immunisation …
Sanofi to acquire Kymab for $1.1bn
January 11, 2021Sales and Marketing Malin, Sanofi, kymab
Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to this upfront sum, Paris-headquartered Sanofi …
Sanofi/GSK COVID-19 vaccine development delayed after failing to induce strong response in over-50s
December 11, 2020Medical Communications, Research and Development COVID-19, GSK, Sanofi, Vaccine
Sanofi and GlaxoSmithKline have taken the decision to delay the development programme for their adjuvanted recombinant protein-based COVID-19 vaccine after …
Dupixent becomes first systemic medicine approved in Europe for children with severe atopic dermatitis
November 30, 2020Sales and Marketing Dupixent, EU, Europe, Sanofi
The European Commission has moved to expand the existing authorisation of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union …
NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura
November 12, 2020Sales and Marketing NHS, NICE, Sanofi, pharma
Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …
Pharmafile.com’s weekly COVID-19 news round-up
November 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir
As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …
Sanofi angles to buy Kiadis for €308 million
November 2, 2020Sales and Marketing Sanofi, kiadis, pharma
Sanofi has announced it is poised to buy out Amsterdam-based biopharma firm Kiadis in an all-cash public offer of €308 …
GSK and Sanofi promise 200m COVID-19 vaccines to international COVAX initiative
October 28, 2020Manufacturing and Production, Research and Development COVAX, COVID-19, GSK, Sanofi
Sanofi and GSK have committed 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine to the COVAX Facility, a …
Latest content
Five Facts about cardiovascular disease
